VCM
LCTX icon

Voleon Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Voleon Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.9K Sell
46,478
-39,261
-46% -$54.3K ﹤0.01% 759
2026
Q1 		$135K Buy
85,739
+14,771
+21% +$24.9K ﹤0.01% 763
2025
Q4 		$119K Buy
+70,968
New +$123K ﹤0.01% 746

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Voleon Capital Management's LCTX Position: Q2 2026 in Review

Voleon Capital Management reduced its Lineage Cell Therapeutics (LCTX) stake by 46% in Q2 2026, selling an estimated $54.3K and leaving 46,478 shares worth $60.9K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Voleon Capital Management first reported a position in LCTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $135K in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Voleon Capital Management held 46,478 shares of Lineage Cell Therapeutics worth $60.9K as of Q2 2026.
  • Voleon Capital Management sold 39,261 Lineage Cell Therapeutics shares in Q2 2026, an estimated $54.3K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Voleon Capital Management's portfolio in Q2 2026, its #759 holding.
  • Voleon Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Voleon Capital Management's Lineage Cell Therapeutics position peaked at $135K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.